Latest News about SPRY
Recent news which mentions SPRY
Earnings Scheduled For August 13, 2025
August 13, 2025
From Benzinga
From Benzinga
Earnings Scheduled For May 14, 2025
May 14, 2025
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 20, 2025
From Benzinga
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
March 20, 2025
From Benzinga
Earnings Scheduled For March 20, 2025
March 20, 2025
From Benzinga
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment
March 06, 2025
From Benzinga
Earnings Scheduled For November 13, 2024
November 13, 2024
From Benzinga
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
November 12, 2024
Tickers
SPRY
From Benzinga
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
November 11, 2024
From Benzinga
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
August 23, 2024
From Benzinga
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
August 20, 2024
From Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
August 20, 2024
From Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
August 13, 2024
From Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
August 09, 2024
From Benzinga
Tickers
SPRY
From InvestorPlace
Top 5 Health Care Stocks That May Plunge In March
March 28, 2024
From Benzinga
Tickers
SPRY
From InvestorPlace
From InvestorPlace
Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
February 26, 2024
From Benzinga
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
February 20, 2024
From Benzinga
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 10, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.